Image of Natasha Archer

Natasha Archer, MD

Instructor in Pediatrics and a Department of Global Health and Social Medicine Affiliate

Natasha Archer, MD, MPH, is a pediatric hematologist/oncologist at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, an instructor in pediatrics at Harvard Medical School, and associate physician in the Division of Global Health Equity at Brigham and Women’s Hospital. She is also the senior health and policy advisor for Hematology at Zanmi Lasante (the Haitian sister organization of Partners In Health). Dr. Archer’s research focuses on the delivery of effective sickle cell disease care to children worldwide. Her research interests include the implementation of sickle cell disease screening and management programs in low resource settings and the effect of different hemoglobins on malaria infectivity. Dr. Archer completed her fellowship in pediatric hematology/oncology at Dana-Farber/Boston Children’s in 2014 and her medicine and pediatrics residency in the Harvard Combined Internal Medicine/Pediatrics Residency training program in 2011. She also completed the Doris and Howard Hiatt Global Health Equity Residency in 2011. Dr. Archer earned her BS from Yale College in 1999, her MD from Yale University School of Medicine in 2006, and her MPH from Harvard School of Public Health in 2011.

Further evidence supporting the global use of hydroxyurea.
Authors: Authors: Archer NM.
Blood Adv
View full abstract on Pubmed
Increasing COVID-19 Vaccination Rates for Children With Sickle Cell Disease.
Authors: Authors: Yan AP, Archer NM, Arnold D, Hansbury E, Heeney MM, Johnson D, Lichtman E, McMullan H, Morrissey L, Ilowite M.
Pediatrics
View full abstract on Pubmed
F-erythrocytes promote Plasmodium falciparum proliferation in sickle cell disease.
Authors: Authors: Archer NM, Gnangnon B, Mikdar M, Ciuculescu MF, Petersen N, Staffa SJ, Duraisingh MT.
Am J Hematol
View full abstract on Pubmed
Genetic reversal of the globin switch concurrently modulates both fetal and sickle hemoglobin and reduces red cell sickling.
Authors: Authors: De Souza DC, Hebert N, Esrick EB, Ciuculescu MF, Archer NM, Armant M, Audureau É, Brendel C, Di Caprio G, Galactéros F, Liu D, McCabe A, Morris E, Schonbrun E, Williams D, Wood DK, Williams DA, Bartolucci P, Higgins JM.
Nat Commun
View full abstract on Pubmed
Diversity, equity, and inclusion: Moving from ambition to action.
Authors: Authors: Archer NM.
Pediatr Blood Cancer
View full abstract on Pubmed
Ketamine use for management of vaso-occlusive pain in pediatric sickle cell disease.
Authors: Authors: Harris EM, Vilk E, Donado C, Williams A, Heeney MM, Solodiuk J, Greco C, Archer NM.
Pediatr Blood Cancer
View full abstract on Pubmed
Intranasal fentanyl works-Why are we not using it more to treat acute pain in sickle cell disease?
Authors: Authors: Oni MO, Archer NM.
Am J Hematol
View full abstract on Pubmed
Patient Controlled Analgesia for Vaso-Occlusive Episodes in Children: A Retrospective Study.
Authors: Authors: Donado C, Harris EM, Heeney MM, Solodiuk JC, Greco CD, Archer NM.
J Pain Symptom Manage
View full abstract on Pubmed
Does fetal hemoglobin inhibit the malarial parasite Plasmodium falciparum?
Authors: Authors: Archer NM, Pasvol G, Wilson I, Duraisingh MT.
Am J Hematol
View full abstract on Pubmed
A seat at the table: A perspective on participation of Black individuals in clinical trials.
Authors: Authors: Edwards JG, Archer NM.
Pediatr Blood Cancer
View full abstract on Pubmed